Savina N.M. The Efficacy of Rivaroxaban in Reducing the Risk of Cardiovascular Events in Patients with Stable Ischemic Heart Disease and Peripheral Disease. Results of the COMPASS Trial. Kardiologiia. 2018;58(3):94-100. (In Russ.) https://doi.org/10.18087/cardio.2018.3.10103
Email this article (Login required)
Email the author (Login required) 
Post a Comment (Login required)
office 215, 5, Beregovoy proezd, Moscow, 121087
Publisher: Regional public organization for popularization of scientific and medical literature "Cardiomag". OGRN 1067799014436
tel.: (495) 211–6994
e-mail: info.cardiomag@gmail.com
